Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingVentura County Biomarker Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy 006

    Biomarker Testing

    Customize your policy alerts

    Sign up for venturacountyhealthcareplan Policy 006 alerts

    Get alerted when Policy 006 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage, utilization management, prior authorization, and appeals for biomarker testing used for diagnosis, treatment, management, or ongoing monitoring. It applies to VCHCP enrollees, with special statutory coverage and prior-authorization rules for cancer and personal history of cancer.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyBiomarker Testing
    Policy CodePolicy 006
    Change TypeRevised statutory coverage and prior-authorization requirements
    Effective DateJul 1, 2024
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionSubmit the applicable cancer diagnosis or personal history of cancer diagnosis code at the point of claims.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was revised to clarify coverage and prior-authorization requirements under Health and Safety Code Sections 1367.665(b) and 1367.667.

    The policy added a list of biomarker-testing CPT and proprietary codes associated with SB 496 coverage.

    The policy clarified that cancer and personal history of cancer diagnosis codes do not require prior authorization when submitted at the point of claims.

    No PACancer or personal history testing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    C00-C96.ZCancer diagnosis codes
    Z85-Z85.9Personal history codes
    81400-81408Advanced cancer CPT range
    11SB 496 code entries
    5Coverage or evidence bases

    Biomarker Testing Coverage Requirements

    Cancer and personal history of cancer

    Covered without prior authorization when either of the following applies:

    ONE of

    • The enrollee has advanced or metastatic stage 3 or 4 cancer, including cancer progression or recurrence.
    • The enrollee has a cancer diagnosis or personal history of cancer, and the applicable diagnosis code is submitted at the point of claims.

    Non-cancer biomarker testing

    Covered with utilization-management review when all applicable requirements are met:

    ALL of

    • The enrollee does not have a cancer diagnosis or personal history of cancer.
    • The biomarker testing is medically necessary for diagnosis, treatment, appropriate management, or ongoing monitoring of a disease or condition to guide treatment decisions.
    • The request satisfies applicable VCHCP medical policy or Milliman Care Guidelines criteria.

      Subject to utilization-management review and prior authorization when required.

    SB 496 coverage basis

    A biomarker test must meet at least one recognized coverage or evidence basis:

    ONE of

    • The test has an FDA-approved or FDA-cleared labeled indication, or is indicated for an FDA-approved drug.
    • A national coverage determination made by the Centers for Medicare and Medicaid Services applies.
    • A local coverage determination made by a Medicare Administrative Contractor for California applies.
    • Evidence-based clinical practice guidelines supported by peer-reviewed literature and peer-reviewed scientific studies apply.
    • The test meets standards set by the National Academy of Medicine.

    Biomarker testing is covered for enrollees without cancer or a personal history of cancer when it is medically necessary for the diagnosis, treatment, appropriate management, or ongoing monitoring of a disease or condition to guide treatment decisions and meets applicable VCHCP medical-policy or Milliman Care Guidelines criteria. These requests are subject to utilization-management review and prior authorization when required.

    Under SB 496, the test must also be supported by at least one recognized coverage or evidence basis, such as an FDA-approved or FDA-cleared labeled indication, a CMS national coverage determination, a California Medicare Administrative Contractor local coverage determination, evidence-based clinical practice guidelines supported by peer-reviewed literature, or National Academy of Medicine standards. Testing that does not meet applicable medical-necessity criteria after review may be restricted or denied.

    Covered Uses of Biomarker Testing

    Diagnosis, treatment, appropriate management, or ongoing monitoring

    Covered when the testing is medically necessary and the applicable coverage pathway is satisfied:

    ALL of

    • Biomarker testing, including whole genome sequencing, is requested for diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition to guide treatment decisions.
    • Applicable coverage pathway

      • The enrollee has a cancer diagnosis or personal history of cancer, or has advanced or metastatic stage 3 or 4 cancer, including cancer progression or recurrence, under the applicable cancer coverage provisions.
      • For an enrollee without cancer or personal history of cancer, the testing meets applicable medical-necessity criteria after utilization-management review.

        Medical necessity is determined using applicable VCHCP medical policies or Milliman Care Guidelines criteria.

    Covered Biomarker Testing Codes

    SB 535 Biomarker for advanced cancerCPTCovered
    81400-81408SB 535 Biomarker for advanced cancer
    SB 496 BiomarkerCPTCovered
    81206BCR/ABL1
    81207BCR/ABL1
    81208BCR/ABL1
    81270JAK2 (p.V617F)
    81479CALR
    81219CALR (exon 9)
    81479CSF3R
    81175ASXL1
    81176ASXL1
    81479TET2
    1–10 of 19
    1/2
    Diagnosis codes for claimsICD-10
    C00-C96.ZCancer diagnosis codes
    Z85-Z85.9History of cancer diagnosis code

    Authorization, Documentation, and Claims Requirements

    Billing Rule

    Cancer and Cancer History Testing

    Biomarker testing is covered without prior authorization for an enrollee with a cancer diagnosis or personal history of cancer when the applicable coverage criteria are met.

    Billing Rule

    Advanced or Metastatic Cancer

    Biomarker testing is covered without prior authorization for advanced or metastatic stage 3 or 4 cancer, including cancer progression or recurrence in an enrollee with advanced or metastatic stage 3 or 4 cancer.

    Unsupported block type: prior_auth

    Billing Rule

    Policy Background

    Biomarker testing may support diagnosis, treatment selection, appropriate disease management, and ongoing monitoring by providing information used to guide treatment decisions. The policy includes medically necessary testing, including whole genome sequencing, for an enrollee’s disease or condition.

    Under SB 496, effective July 1, 2024, coverage is subject to medical-necessity review and is supported when the test has an FDA-approved or FDA-cleared labeled indication, relates to an FDA-approved drug, is addressed by a CMS national or California Medicare Administrative Contractor local coverage determination, is supported by evidence-based clinical practice guidelines and peer-reviewed literature, or meets National Academy of Medicine standards. Cancer-related testing is subject to separate statutory coverage and prior-authorization rules, including no prior authorization when applicable cancer or personal-history diagnosis codes are submitted at the point of claims.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyBiomarker Testing
    Policy CodePolicy 006
    Change TypeRevised statutory coverage and prior-authorization requirements
    Effective DateJul 1, 2024
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionSubmit the applicable cancer diagnosis or personal history of cancer diagnosis code at the point of claims.
    SourceLink
    On This Page
    Biomarker Testing Coverage RequirementsCovered Uses of Biomarker TestingCovered Biomarker Testing CodesAuthorization, Documentation, and Claims RequirementsPolicy Background

    Advanced or metastatic stage 3 or 4 cancer, including progression or recurrence

    Covered without prior authorization under SB 535:

    ALL of

    • The enrollee has advanced or metastatic stage 3 or 4 cancer.
    • ONE of

      • The biomarker testing is for advanced or metastatic stage 3 or 4 cancer.
      • The cancer has progressed or recurred.

    Submit Applicable Cancer Diagnosis Codes

    At the point of claims submission, providers must report the applicable cancer or personal history of cancer ICD-10 diagnosis code when billing biomarker testing.

    • Cancer diagnosis codes: C00 through C96.Z
    • Personal history of cancer diagnosis codes: Z85 through Z85.9
    • Diagnosis codes in these ranges do not require prior authorization.
    Documentation Required

    Support Medical Necessity and Coverage Basis

    Documentation must support the requested biomarker test and the applicable coverage basis for diagnosis, treatment, appropriate management, or ongoing monitoring to guide treatment decisions.

    • FDA-approved or FDA-cleared labeled indication, or an indicated test for an FDA-approved drug
    • National coverage determination by the Centers for Medicare and Medicaid Services
    • Local coverage determination by a Medicare Administrative Contractor for California
    • Evidence-based clinical practice guidelines supported by qualifying peer-reviewed literature or scientific studies
    • Standards established by the National Academy of Medicine
    Denial Risk

    Medical Necessity Required

    When medical-necessity requirements are not met, biomarker testing for an enrollee without cancer or a personal history of cancer may be restricted or denied following utilization-management review.

    • The Plan follows its disclosed utilization-management process and applicable medical policies or criteria when authorizing, modifying, or denying services.
    • Providers may request the Plan's utilization-management policies, procedures, and criteria used for determinations.
    Denial Risk

    Restricted or Denied Testing

    Testing used for diagnosis, treatment, appropriate management, or ongoing monitoring of another medical condition may be restricted or denied when coverage and medical-necessity requirements are not met. Restricted or denied biomarker testing is subject to the Plan's grievance and appeal processes, and care should be managed to limit disruption, including the need for multiple biopsies or biospecimen samples.

    • The Plan provides notifications of decisions to deny, delay, or modify requested services in accordance with applicable requirements.
    • Members and providers may use the Plan's grievance and appeal processes to dispute a restriction or denial.